Latest Ratios: P/E Ratio 971.3x · EV/EBITDA 23.4x · ROE 0.2%. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $2.1B | $2.1B | $1.7B | $2.3B | $8.7B | $5.3B | $3.5B | $2.5B | $1.9B | $1.2B |
| Enterprise Value | $2.0B | $2.1B | $2.1B | $1.8B | $2.6B | $8.8B | $5.3B | $3.5B | $2.6B | $2.1B | $1.4B |
| P/E Ratio → | 971.33 | 1022.57 | 164.89 | — | 420.17 | 111.38 | 162.19 | 57.15 | 65.85 | 61.39 | 130.38 |
| P/S Ratio | 1.65 | 1.77 | 1.85 | 1.48 | 1.79 | 7.64 | 5.88 | 3.91 | 3.15 | 2.62 | 1.80 |
| P/B Ratio | 1.62 | 1.70 | 1.66 | 1.43 | 2.05 | 7.54 | 5.43 | 4.15 | 3.65 | 3.63 | 2.90 |
| P/FCF | 22.52 | 24.17 | 13.61 | 12.19 | 135.78 | 42.65 | 40.08 | 42.11 | 50.09 | — | 66.57 |
| P/OCF | 15.37 | 16.50 | 10.97 | 9.39 | 29.75 | 37.32 | 28.25 | 24.20 | 23.89 | 75.60 | 26.07 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.78 | 1.86 | 1.61 | 2.01 | 7.81 | 5.93 | 3.89 | 3.24 | 2.87 | 2.09 |
| EV / EBITDA | 23.40 | 25.11 | 23.01 | 24.24 | 26.85 | 50.69 | 49.41 | 24.52 | 26.66 | 35.89 | 22.35 |
| EV / EBIT | 380.76 | 120.53 | 6150.20 | — | — | 98.79 | 148.97 | 44.58 | 57.49 | 184.41 | 67.71 |
| EV / FCF | — | 24.26 | 13.70 | 13.23 | 152.58 | 43.59 | 40.40 | 41.91 | 51.46 | — | 77.21 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 42.5% | 42.5% | 42.3% | 43.6% | 45.4% | 49.0% | 46.3% | 48.7% | 47.3% | 45.0% | 45.3% |
| Operating Margin | 0.4% | 0.4% | 0.0% | -1.7% | -0.2% | 7.9% | 4.0% | 8.7% | 5.6% | 0.8% | 0.9% |
| Net Profit Margin | 0.2% | 0.2% | 1.1% | -1.8% | 0.4% | 6.9% | 3.6% | 6.8% | 4.8% | 2.9% | 0.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 0.2% | 0.2% | 1.0% | -1.8% | 0.5% | 7.4% | 3.6% | 8.0% | 6.3% | 4.3% | 0.1% |
| ROA | 0.1% | 0.1% | 0.6% | -0.9% | 0.3% | 3.9% | 2.1% | 5.3% | 3.7% | 2.2% | 0.1% |
| ROIC | 0.3% | 0.3% | 0.0% | -1.1% | -0.1% | 5.7% | 2.9% | 7.5% | 4.6% | 0.7% | 1.0% |
| ROCE | 0.3% | 0.3% | 0.0% | -1.1% | -0.2% | 6.4% | 2.8% | 8.3% | 5.4% | 0.8% | 1.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.17 | 0.31 | 0.52 | 0.55 | 0.47 | 0.55 | 0.13 | 0.20 | 0.41 | 0.59 |
| Debt / EBITDA | 2.43 | 2.43 | 4.25 | 8.06 | 6.37 | 3.10 | 4.93 | 0.78 | 1.41 | 3.67 | 3.92 |
| Net Debt / Equity | — | 0.01 | 0.01 | 0.12 | 0.25 | 0.17 | 0.04 | -0.02 | 0.10 | 0.34 | 0.46 |
| Net Debt / EBITDA | 0.09 | 0.09 | 0.15 | 1.92 | 2.96 | 1.10 | 0.40 | -0.12 | 0.71 | 3.10 | 3.08 |
| Debt / FCF | — | 0.09 | 0.09 | 1.05 | 16.81 | 0.95 | 0.32 | -0.20 | 1.38 | — | 10.64 |
| Interest Coverage | 2.84 | 2.84 | 0.07 | — | -17.87 | 4.00 | 16.94 | 13.50 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | 1.43 | 1.37 | 2.52 | 2.06 | 0.89 | 3.00 | 2.04 | 1.94 | 1.73 | 1.74 |
| Quick Ratio | 1.22 | 1.22 | 1.22 | 2.22 | 1.71 | 0.75 | 2.65 | 1.58 | 1.45 | 1.28 | 1.36 |
| Cash Ratio | 0.41 | 0.41 | 0.64 | 1.27 | 0.80 | 0.41 | 1.79 | 0.58 | 0.33 | 0.15 | 0.30 |
| Asset Turnover | — | 0.60 | 0.52 | 0.52 | 0.59 | 0.53 | 0.49 | 0.72 | 0.73 | 0.73 | 0.74 |
| Inventory Turnover | 6.75 | 6.75 | 7.23 | 5.88 | 4.79 | 4.81 | 4.97 | 4.26 | 4.11 | 4.10 | 5.47 |
| Days Sales Outstanding | — | 66.80 | 84.14 | 83.97 | 84.34 | 77.67 | 77.78 | 88.85 | 90.98 | 101.33 | 79.21 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.1% | 0.1% | 0.6% | — | 0.2% | 0.9% | 0.6% | 1.7% | 1.5% | 1.6% | 0.8% |
| FCF Yield | 4.4% | 4.1% | 7.3% | 8.2% | 0.7% | 2.3% | 2.5% | 2.4% | 2.0% | — | 1.5% |
| Buyback Yield | 4.0% | 3.7% | 0.0% | 0.0% | 2.3% | 0.2% | 1.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Total Shareholder Yield | 4.0% | 3.7% | 0.0% | 0.0% | 2.3% | 0.2% | 1.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Shares Outstanding | — | $46M | $46M | $45M | $46M | $48M | $44M | $43M | $41M | $39M | $37M |
Hospital CAPEX budget sensitivity
Based on reported figures, Omnicell trades at a TTM P/E of 905.87, which appears to reflect significant market optimism regarding future margin expansion rather than current earnings power, especially when compared to the more stable valuation multiples observed in diversified healthcare peers like Becton Dickinson.
The extreme P/E ratio suggests that investors are pricing in a substantial recovery in profitability as the company transitions toward a subscription-based model. However, the forward P/E of 20.71 indicates that the market expects a rapid normalization of earnings, which may be overly optimistic given the historical sensitivity of the company's margins to hospital capital expenditure cycles.
As reported in financial statements, Omnicell's ROIC has struggled to gain traction, fluctuating between a low of -1.3% in 2023Q4 and a modest 1.0% in 2026Q1, indicating that the company is currently failing to generate returns that exceed its cost of capital.
The persistent inability to drive meaningful returns on invested capital suggests that the heavy R&D and M&A spending has yet to translate into a scalable competitive advantage. Investors should monitor whether the shift toward Advanced Services can eventually drive the ROIC into positive territory, or if the current capital structure remains inefficiently deployed.
According to recent quarterly data, Omnicell's cash conversion cycle remains elevated at 94 days in 2026Q1, reflecting structural inefficiencies in inventory management and customer payment terms that continue to tie up capital within the company's complex hardware-heavy business model.
The high DIO and DSO figures suggest that the company faces significant friction in converting its installed base into cash, likely exacerbated by the long implementation timelines for its automated dispensing systems. This inefficiency forces the company to maintain higher liquidity buffers than would be required by a pure-play software provider.
Based on the provided quarterly data, Omnicell has successfully reduced its debt-to-equity ratio from 0.52 in 2024Q1 to 0.15 in 2026Q1, signaling a deliberate and effective strategy to strengthen the balance sheet despite the ongoing volatility in its core operating performance.
This reduction in financial leverage provides a necessary cushion against the cyclical nature of hospital spending, effectively lowering the company's interest coverage risk. While the balance sheet is now significantly healthier, the company must now demonstrate that this financial stability can be leveraged to drive sustainable growth rather than just defensive positioning.
The P/E ratio is frequently misapplied to Omnicell because it obscures the impact of heavy stock-based compensation and acquisition-related amortization, which often cause reported net income to deviate significantly from the actual cash-generating capacity of the underlying pharmacy automation business model.
Analysts should instead focus on EV/EBITDA or free cash flow yield to better understand the company's operational performance, as these metrics are less distorted by non-cash accounting charges. Relying on P/E in this context may lead to an inaccurate assessment of the company's true valuation and its ability to fund future growth.
Includes 30+ ratios · 26 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OMCL stock.
Omnicell, Inc.'s current P/E ratio is 971.3x. The historical average is 68.9x. This places it at the 100th percentile of its historical range.
Omnicell, Inc.'s current EV/EBITDA is 23.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.1x.
Omnicell, Inc.'s return on equity (ROE) is 0.2%. The historical average is 5.0%.
Based on historical data, Omnicell, Inc. is trading at a P/E of 971.3x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Omnicell, Inc. has 42.5% gross margin and 0.4% operating margin.
Omnicell, Inc.'s Debt/EBITDA ratio is 2.4x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.